سعر ALOXI 0.25MG/5ML VIAL FOR I.V. 2026

Aloxi 0.25 mg/5 ml solution for intravenous injection, single vial (Mundipharma; marketed by Multipharma in Egypt): palonosetron, a selective 5-HT3 antagonist for prevention of chemotherapy-induced nausea and vomiting.

• Most frequent in adults at 250 micrograms: headache (9%) and constipation (5%); common: dizziness, diarrhoea; very rare post-marketing: hypersensitivity/anaphylaxis and injection-site reactions.International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to palonosetron or to any of the excipients.International label, same formulation · European Medicines Agency (EPAR product information)
• Known hypersensitivity to the drug or any of its components.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• May increase large-bowel transit time: monitor patients with a history of constipation or signs of subacute intestinal obstruction.International label, same formulation · European Medicines Agency (EPAR product information)
• Caution in patients who have or may develop QT prolongation (personal/family history, electrolyte abnormalities, heart failure, bradyarrhythmias, conduction disturbances, antiarrhythmics or QT-prolonging drugs); correct hypokalaemia and hypomagnesaemia first.International label, same formulation · European Medicines Agency (EPAR product information)
• Serotonin syndrome has been reported with 5-HT3 antagonists alone or with other serotonergic drugs (SSRIs, SNRIs); observe patients.International label, same formulation · European Medicines Agency (EPAR product information)

• Serotonergic drugs (SSRIs, SNRIs)Serotonin syndrome reported with concomitant 5-HT3 antagonists and serotonergic drugs.European Medicines Agency (EPAR product information)
• CYP2D6 inducers/inhibitorsNo significant effect on palonosetron clearance with CYP2D6 inducers (dexamethasone, rifampicin) or inhibitors in population PK analysis.European Medicines Agency (EPAR product information)

• No clinical data on exposed pregnancies; animal studies show no harmful effects. Should not be used in pregnancy unless considered essential by the physician.International label, same formulation · European Medicines Agency (EPAR product information)
• No data on excretion in breast milk; breastfeeding should be discontinued during therapy.International label, same formulation · European Medicines Agency (EPAR product information)
• Unknown whether excreted in human milk; decide whether to discontinue nursing or the drug, considering its importance to the mother.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Palonosetron (as hydrochloride): Selective high-affinity antagonist of serotonin 5-HT3 receptors.